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 The antineoplastic properties of aspirin and other nonsteroidal 
anti-infl ammatory drugs (NSAIDs) have been documented in 
many observational studies and randomized trials ( 1 – 4 ). However, 
most observational studies suggest that this protective effect dissi-
pates after discontinuing regular use [reviewed in ( 3 )], and the data 
regarding the persistence of the effect are not extensive ( 5 ). 
Recently, we reported that the protective effects of calcium supple-
mentation on the risk of colorectal adenoma recurrence persisted 
up to 5 years after the end of randomized treatment ( 6 ), with a 
statistically signifi cant 37% lower risk for all adenomas for the 
calcium group compared with the placebo group, suggesting a 
long-term antineoplastic effect. However, another randomized 
trial that studied a selective cyclooxygenase (COX)-2 inhibitor, 
rofecoxib, reported a rebound in the incidence of colorectal ade-
nomas in the rofecoxib group, with a statistically signifi cant 21% 
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 ARTICLE 
 Nonsteroidal Anti-inflammatory Drug Use After 
3 Years of Aspirin Use and Colorectal Adenoma Risk: 
Observational Follow-up of a Randomized Study 
 Maria V.  Grau ,  Robert S.  Sandler ,  Gail  McKeown-Eyssen ,  Robert S.  Bresalier ,  Robert W.  Haile ,  Elizabeth 
L.  Barry ,  Dennis J.  Ahnen ,  Jiang  Gui ,  Robert W.  Summers ,  John A.  Baron 
  Background  Frequent use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to reduce the risk of col-
orectal adenomas in randomized trials. We examined the persistence of the protective effect after the 
cessation of randomized aspirin treatment and whether it is affected by the duration and frequency of 
subsequent NSAID use. 
  Methods  We used data from the Aspirin/Folate Polyp Prevention Study (AFPPS), in which 1121 subjects were ran-
domly assigned to receive placebo or aspirin (81 or 325 mg/d) for 3 years. After the end of treatment and 
a follow-up colonoscopy, AFPPS participants were invited to remain under follow-up until their next sur-
veillance colonoscopies, scheduled 3 – 5 years later. Information regarding use of NSAIDs during posttreat-
ment follow-up was gathered periodically via questionnaires. Average weekly NSAID use was classified as 
sporadic (<2 days per week), moderate (2 to <4 days per week), or frequent ( ≥ 4 days per week). The analy-
sis was stratified according to randomized aspirin groups and posttreatment NSAID use; placebo subjects 
who later were sporadic NSAID users formed the reference group. The primary outcomes were all ade-
nomas and advanced lesions. Adjusted relative risks and 95% confidence intervals were computed with 
generalized linear models. All statistical tests were two-sided. 
  Results  A total of 850 subjects underwent a posttreatment colonoscopy, on average 4 years after the end of study 
treatment. The protective effect of 81 mg of aspirin for colorectal adenomas persisted with continued post-
treatment NSAID use. The risk of any adenoma among frequent NSAID users was 26.8% vs 39.9% among 
placebo subjects who later used NSAIDs sporadically (adjusted relative risk = 0.62, 95% confidence inter-
val [CI] = 0.39 to 0.98;  P trend with NSAID use frequency = .03). The unadjusted absolute risk reduction was 
13.1 percentage points (95% CI = −0.3 to 26.5 percentage points) ( P = .07). Results for 325 mg of aspirin 
were similar, although not statistically significant. For advanced lesions, small numbers of endpoints lim-
ited the analysis, but findings among subjects randomly assigned to 81 mg of aspirin suggested a protec-
tive association regardless of posttreatment NSAID use. 
  Conclusion  Long-term and frequent use of NSAIDs may enhance the chemopreventive effect of aspirin against col-
orectal neoplasia. 
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increased risk 1 year after treatment cessation ( 7 ). These results 
emphasize the importance of investigating patterns of risk after a 
chemopreventive agent is stopped. 
 This analysis was designed to address the following questions: 
1) Is the protective effect of aspirin on the risk of colorectal ade-
nomas durable, or does it diminish with sustained use (tachyphy-
laxis)? 2) Is there a carryover protective effect for aspirin, similar to 
the effect of calcium, or is there an increased risk after discontinu-
ation, similar to what was seen for rofecoxib? 3) Do these effects 
hold for both all adenomas and advanced lesions? 
 Materials and Methods 
 Study Design 
 Details of and findings from the Aspirin/Folate Polyp Prevention 
Study (AFPPS) have been previously published ( 1 , 8 ). Briefly, 
AFPPS is a double-blind, placebo-controlled randomized trial 
(clinicaltrials.gov Identifier: NCT00272324) to assess the antine-
oplastic effects of aspirin and folate in subjects with a recent his-
tory of colorectal adenomas. Nine clinical centers took part in the 
trial. Originally, the study was designed to evaluate aspirin as a 
chemopreventive agent by comparing three treatment arms: 
placebo, 81 mg of aspirin per day, and 325 mg of aspirin per day. 
Shortly after enrollment began (100 subjects had already been 
randomly assigned to aspirin or placebo), the trial was expanded to 
a 3 × 2 factorial design to incorporate the additional randomization 
of each treatment arm to 1 mg of folic acid per day or folate pla-
cebo. Human subjects committees at each institution approved the 
research. All participants provided written informed consent. 
 AFPPS recruitment began on July 6, 1994, and ended on 
March 20, 1998. Eligible subjects had at least one of the following: 
one or more histologically confi rmed colorectal adenomas removed 
within 3 months before recruitment, one or more histologically 
confi rmed adenomas removed within 16 months before recruit-
ment and a lifetime history of two or more confi rmed adenomas, 
or a histologically confi rmed adenoma at least 1 cm in diameter 
removed within 16 months before recruitment. We also required 
a complete colonoscopy within 3 months before enrollment, with 
no known polyps left in the bowel. At enrollment, eligible subjects 
completed a questionnaire regarding personal characteristics, 
medical history, and lifestyle habits, and they were asked to avoid 
the use of aspirin, NSAIDs, and supplements containing folate for 
the duration of active treatment. Potential participants then 
entered a 3-month, single-blind run-in period, during which sub-
jects were asked to take the folate placebo and 325 mg of aspirin 
per day. Subjects with at least 80% compliance and no adverse 
effects to aspirin were randomly assigned to receive (aspirin) pla-
cebo, low-dose aspirin (81 mg/d), or high-dose aspirin (325 mg/d), 
and to receive (folate) placebo or folate (1 mg/d). 
 A follow-up colonoscopy was scheduled for 3 years after the 
qualifying examination. After the 3-year colonoscopy, subjects 
discontinued randomized aspirin treatment but were invited to 
continue randomized study treatment with folate or folate placebo. 
All subjects were also invited to remain under follow-up until the 
next surveillance colonoscopy, as scheduled by their physicians, 
usually 3 – 5 years after the 3-year examination, which occurred at 
the end of randomized aspirin treatment. Subjects could decline to 
participate in this second phase and exit the study, continue blinded 
randomized treatment with folate or placebo (active folate exten-
sion), or remain in the study under observational follow-up but 
discontinue randomized folate treatment (observational extension). 
 The primary outcome of AFPPS — adenoma occurrence — was 
determined by colonoscopy and pathology review ( Figure 1 ). 
Information regarding any intestinal endoscopy or surgery that 
occurred during the study was obtained from the clinical centers. 
In addition to routine pathological assessment at each clinical cen-
ter, histological slides of each lesion removed from the bowel dur-
ing the study were sent to the AFPPS pathologist (Dale C. Snover, 
Department of Pathology, Fairview Southdale Hospital, 
Minneapolis, MN) for uniform review of the pathological diagno-
ses. Advanced adenomas were defi ned as neoplastic polyps with a 
villous component of at least 25 % or that contained advanced 
dysplasia or invasive cancer, or with an estimated diameter of 
at least 1 cm (as assessed by the endoscopist). 
 Participants completed a study questionnaire every 4 months 
(if they were taking study pills) or annually (if they were under 
observational follow-up). The questionnaires collected informa-
tion regarding the occurrence of important medical events (eg, 
intestinal procedures, overnight hospitalizations, cancer, stroke, 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Randomized trials have demonstrated that aspirin and other non-
steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of col-
orectal adenomas. However, it is unclear whether this protective 
effect persists after the cessation of randomized NSAID treatment 
and/or is affected by the duration and frequency of subsequent 
NSAID use. 
 Study design 
 An observational follow-up of the Aspirin/Folate Polyp Prevention 
Study, in which 1121 subjects who were randomly assigned to 
receive placebo or aspirin for 3 years were, after the end of treat-
ment and a follow-up colonoscopy, invited to remain under fol-
low-up until their next surveillance colonoscopies. Information 
regarding the subject ’ s use of NSAIDs and other medications dur-
ing follow-up was obtained periodically via questionnaires. 
 Contribution 
 The risk of all adenomas was substantially reduced among sub-
jects who continued to use NSAIDs after 3 years of aspirin treat-
ment in the randomized trial. There was an apparent strengthening 
of the chemopreventive effect of aspirin associated with use of 
NSAID for at least 4 days per week. 
 Implications 
 Long-term and frequent use of NSAIDs may enhance the chemo-
preventive effect of aspirin against colorectal neoplasia. 
 Limitations 
 Due to the observational nature of the study, the findings are sus-
ceptible to bias and confounding. The study subjects are not repre-
sentative of the general population. Small numbers of advanced 
lesions limited the statistical power of some analyses. The ques-
tionnaires did not capture dose information. 
 From the Editors 
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myocardial infarction, gastrointestinal bleeding), the occurrence of 
intestinal surgery or endoscopy, their use of aspirin and/or 
NSAIDs and other over-the-counter and prescribed medications 
and dietary supplements, and their adherence to study treatment 
since the previous questionnaire. The study questionnaires also 
contained a list of the most commonly used NSAIDs at the time 
(24 drugs, including aspirin-based medications). Participants were 
asked to report the total number of days that they had taken each 
of the listed products since the date the previous questionnaire was 
completed. All follow-up ended on December 31, 2006. 
 Statistical Analysis 
 Our aim was to explore the effects of long-term use of NSAIDs on 
the occurrence of neoplastic colorectal polyps after 3 years of aspi-
rin treatment. Of the 1121 subjects who were randomly assigned to 
receive aspirin or placebo, 1007 completed the 3-year aspirin treat-
ment period and agreed to participate in posttreatment follow-up 
(with or without randomized folate treatment). Of these 1007 sub-
jects, 850 underwent at least one colonoscopy after the original 
year 3 examination but before December 31, 2006, and were 
included in this analysis ( Figure 2 ). For the purpose of this analysis, 
we focused solely on randomized aspirin treatment (randomized 
period) and the self-reported use of NSAIDs after the end of ran-
domized aspirin treatment (observational follow-up) ( Figure 1 ). 
 Fisher exact tests (for categorical variables) and analysis of vari-
ance (for continuous variables) were used to compare randomized 
treatment groups. We also compared the 850 subjects included in 
this analysis with the 138 subjects who continued in the study after 
the end of randomized aspirin treatment but did not have a 
colonoscopy during the posttreatment follow-up phase. 
 Because 90% of the subjects who had any posttreatment 
follow-up examinations had only one such colonoscopy ( Table 1 ), we 
defi ned our primary outcome as the occurrence of adenomas that 
were detected in the fi rst colonoscopy performed at least 6 months 
after the end of randomized aspirin treatment but before December 
31, 2006 ( Figure 1 ). Exclusion of colonoscopies performed within 
1 – 2 years after the termination of aspirin treatment did not materi-
ally affect the fi ndings, and thus, we do not present these analyses. 
We also evaluated the occurrence of small tubular adenomas and 
advanced lesions in separate analyses. 
 We took into account participants ’ responses on all question-
naires that were completed after the end of randomized aspirin 
treatment and up to the fi rst posttreatment colonoscopy to assess 
NSAID use ( Figure 1 ). The questionnaires asked participants for 
the number of days they had used each of the NSAIDs reported 
(including aspirin-based medications) since they had completed 
the previous questionnaire. We used this information to calculate 
the total number of days of NSAID use during the observational 
follow-up and computed the average weekly NSAID use during 
this period. On the basis of the distribution of NSAID use in the 
study cohort, we classifi ed subjects as sporadic NSAID users (aver-
age use <2 days per week), moderate NSAID users (average use 
2 to <4 days per week), or frequent NSAID users (average use 
 ≥ 4 days per week). These groups were compared with regard to 
characteristics at baseline (ie, before randomization) and at fol-
low-up by use of Fisher exact tests (for categorical variables) and 
analysis of variance (for continuous variables). Subjects were strati-
fi ed into nine groups by their randomized treatment assignment 
and their NSAID use during observational follow-up ( Figure 1 ); 
those who had been randomly assigned to placebo and who later 
were sporadic NSAID users were used as the reference group in 
the primary analysis. Subjects who reported taking no NSAIDs at 
all after the end of aspirin treatment were used as the reference 
group in a separate analysis. Because of the small numbers of sub-
jects who had advanced lesions detected during the posttreatment 
follow-up (63 sporadic NSAID users, seven moderate NSAID 
users, and 15 frequent NSAID users), we combined moderate and 
frequent NSAID users into one category (“NSAID users”) in the 
analysis that used advanced lesions as the outcome while maintain-
ing the same reference category. 
 Generalized linear models for the Poisson distribution with a 
natural logarithm link function and adjustment for over- or 
 Figure 1 .  Analytic design. We focused on two 
exposures: ASA treatment assignment during the 
randomized study period (subjects were ran-
domly assigned to placebo, 81 mg of ASA per day 
[ASA 81], or 325 mg of ASA per day [ASA 325]) 
and self-reported use of NSAIDs (<2, 2 – 4, or 
 ≥ 4 days per week) during the posttreatment F/U 
period. The primary outcome was defi ned as the 
occurrence of adenoma in the fi rst posttreatment 
F/U colonoscopy. *Results have been published 
( 1 ). ASA = aspirin; F/U = follow-up; NSAIDs = 
nonsteroidal anti-infl ammatory drugs. 
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underdispersion of the data ( 8 ) were used to compute the relative 
risks and 95% confi dence intervals of having at least one adenoma. 
Adjusted models included age, time to fi rst colonoscopy after the 
end of randomized treatment, number of lifetime adenomas before 
randomization (as continuous variables), body mass index (<25, 
25 – 30,  ≥ 30 kg/m 2 ) at study enrollment (ie, before randomization), 
sex, clinical center, and the presence of adenomas during the ran-
domized aspirin treatment (yes, no) as indicator variables . In addi-
tion, we conducted secondary analyses with further adjustment for 
randomized folate treatment, fi rst-degree family history of col-
orectal cancer (yes, no), cigarette smoking status (never, former, 
current), and alcohol use (yes, no). Inclusion of these covariates in 
the models did not materially change the results; thus, only the 
most parsimonious models are presented. To evaluate response 
trends according to the frequency of NSAID use, we coded spo-
radic, moderate, and frequent NSAID use as 0, 1, and 2, respec-
tively, and used this coding as a continuous variable.  P values were 
computed with two-sided Wald tests. Because of the small number 
of advanced lesions in some exposure categories, crude rather than 
adjusted models might be more statistically appropriate for analy-
ses of this endpoint. However, because unadjusted and adjusted 
estimates in this analysis were very similar, for consistency of pre-
sentation, we present only the adjusted estimates for all adenomas 
and for advanced lesions. A Pearson chi-square goodness-of-fi t test 
was used to evaluate our models, and no statistically signifi cant lack 
of fi t was found. We used 2 × 2 contingency tables and Pearson 
chi-square tests to assess unadjusted absolute risk reductions. 
 The possibility that randomized folate treatment assignment or 
adenoma occurrence during the randomized aspirin treatment 
period could modify our fi ndings was evaluated with product inter-
action terms and Wald tests in separate analyses. Two-sided 
 P values less than .05 were considered to indicate statistical signifi -
cance. All statistical tests were two-sided. 
 Results 
 Characteristics of the subjects in the three aspirin treatment arms 
are summarized in  Table 1 . There were no statistically significant 
differences among the three arms with regard to demographic and 
lifestyle factors at AFPPS study entry, including age, sex, race, 
body mass index, first-degree family history of colorectal cancer, 
alcohol use, cigarette smoking status, and the lifetime number of 
adenomas before randomization. The three treatment groups were 
also similar with regard to the percentage of subjects who were 
randomly assigned to folate treatment, the duration of aspirin 
treatment, or the use of nonprotocol NSAIDs during the random-
ized treatment period. However, as suggested by previously pub-
lished findings ( 1 ), subjects who were randomly assigned to receive 
low-dose aspirin were less likely than subjects in the other two 
treatment arms to have an adenoma detected during the 3-year 
 Figure 2 .  Study fl ow diagram for the random-
ized study period and the posttreatment 
observational follow-up period. *Other rea-
sons for exclusion before randomization: one 
died, 47 ineligible for reasons related to the 
folate component (eg, anemia), 28 concurrent 
illnesses, 26 declined to continue, and 17 
other reasons. ASA = aspirin; NSAID = non-
steroidal anti-infl ammatory drug. 
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treatment period ( P = .080). Posttreatment follow-up characteris-
tics were also comparable across the three randomized aspirin 
groups. Of the 850 subjects included in this analysis, 764 (90%) 
had one colonoscopy and 86 (10%) had two or more colonoscopies 
during the observational follow-up after the end of aspirin treat-
ment. The average time from the end of the study treatment to the 
first posttreatment endoscopy was 45.8 months (SD = 14.4 
months). During this time, the median number of study question-
naires completed by subjects was 9 (interquartile range = 4 – 12; 17 
subjects did not complete any questionnaires). The response rate 
for the study questionnaires (the number completed as a propor-
tion of the number expected) was approximately 85%. The most 
commonly used NSAIDs were the same in the three treatment 
groups: aspirin and aspirin-based drugs (used by 59% of subjects), 
ibuprofen (used by 46%), naproxen (used by 20%), rofecoxib (used 
by 8%), and celecoxib (used by 8%). 
 In general, subjects who had a posttreatment colonoscopy were 
similar to the 138 subjects who did not have a posttreatment 
colonoscopy with regard to demographic and lifestyle factors. 
However, subjects with a posttreatment colonoscopy were more 
likely to have had adenomas during the treatment phase of the 
study (47% vs 22%,  P < .001) and advanced lesions (11% vs 5%, 
 P = .03) detected during the 3-year aspirin treatment period. 
 Among the 833 subjects who completed posttreatment ques-
tionnaires, 589 (71%) took NSAIDs at most intermittently and 
were classifi ed as sporadic users (average use <2 days per week), 96 
(12%) were moderate users (average use 2 to <4 days per week), 
and 148 (18%) were frequent users (average use  ≥ 4 days per week); 










(n = 281) 
 Before randomization in AFPPS 
  Mean age, y (SD) 57.5 (9.3) 57.6 (9.1) 57.7 (9.0) 
  Male subjects, No. (%) 181 (64) 189 (67) 177 (63) 
  Race, No. (%) 
   White 238 (84) 252 (89) 251 (89) 
   Black 19 (7) 15 (5) 8 (3) 
   Hispanic 19 (7) 9 (3) 13 (5) 
   Other 9 (2) 8 (3) 9 (3) 
  Body mass index in kg/m 2 , No. (%) 
   <25 85 (30) 88 (31) 86 (31) 
   25 to <30 140 (49) 133 (47) 134 (48) 
   ≥ 30 59 (21) 62 (22) 61 (22) 
  Alcohol user, No. (%) 195 (73) 181 (66) 195 (71) 
  Cigarette smoking status, No. (%) 
   Never 132 (46) 128 (45) 107 (38) 
   Former 114 (40) 115 (41) 135 (48) 
   Current 38 (13) 40 (14) 38 (14) 
  Positive first-degree family history of colorectal cancer, No. (%) 79 (34) 89 (37) 102 (45) 
  Mean lifetime no. of adenomas (SD) 2.4 (2.2) 2.3 (1.9) 2.6 (2.5) 
 During randomized aspirin treatment period 
  Randomized folate treatment assignment, No. (%) 133 (51) 137 (52) 136 (53) 
  Mean time on randomized aspirin treatment, mo (SD) 32.7 (3.7) 32.3 (2.9) 32.6 (3.4) 
  Frequency of nonprotocol NSAID use during the randomized period in days per month, 
   No. (%) 
   0 208 (73) 218 (77) 213 (76) 
   1 – 4 53 (19) 42 (15) 49 (17) 
   >4 24 (8) 24 (8) 19 (7) 
  Subjects with adenomas at treatment completion, No. (%) 143 (50) 118 (42) 138 (49) 
 During posttreatment observational follow-up period 
  Colonoscopies, No. (%) 
   1 253 (89) 260 (92) 251 (89) 
   2 28 (10) 20 (7) 23 (8) 
   ≥ 3 4 (1) 4 (1) 7 (3) 
  Subjects whose first posttreatment colonoscopy reached the cecum, No. (%) 273 (96) 267 (94) 271 (96) 
  Mean time from the end of treatment to first colonoscopy, mo (SD) 44.9 (14.1) 47.7 (14.7) 44.8 (14.4) 
  Median no. of questionnaires completed up to the first posttreatment colonoscopy (IQR) 9 (4 – 11) 9 (4 – 13) 9 (4 – 10) 
  Frequency of NSAIDs use before the first colonoscopy in days per week † , No. (%) 
   <2 203 (73) 194 (70) 192 (69) 
   2 – 4 32 (12) 28 (10) 36 (13) 
   ≥ 4 43 (15) 56 (20) 49 (18) 
 *  AFPPS = Aspirin/Folate Polyp Prevention Study; low-dose aspirin = 81 mg; high-dose aspirin = 825 mg; NSAID = nonsteriodal anti-inflammatory drug; 
IQR = interquartile range. 
 †  Seventeen subjects did not complete any questionnaire from the end of aspirin treatment to the first posttreatment colonoscopy. 
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165 subjects (20%) reported no NSAID use at all ( Table 1 ). 
Frequent NSAID users were similar to subjects with less frequent 
NSAID use with regard to most demographic, lifestyle, and clini-
cal factors (data not shown). However, frequent NSAID users were 
statistically signifi cantly older ( P = .01) and had a higher body mass 
index ( P = .03) than the sporadic or moderate NSAID users. 
 The effects of aspirin use on adenoma risk during the treatment 
phase of the trial are summarized in  Table 2 . As reported previ-
ously ( 1 ), aspirin treatment moderately reduced the risk of colorec-
tal adenomas; the adjusted relative risk for all adenomas for the two 
aspirin groups combined vs the placebo group was 0.90 (95% con-
fi dence interval [CI] = 0.77 to 1.05). When we considered each 
aspirin group independently, a borderline statistically signifi cant 
risk reduction was observed for the low-dose aspirin group 
(adjusted relative risk [RR] = 0.84, 95% CI = 0.70 to 1.00). 
 The protective effect of randomization to one of the aspirin 
groups persisted during the posttreatment period for subjects who 
continued to use aspirin or other NSAIDs, and there was a statisti-
cally signifi cant trend of decreasing risk with increasing frequency 
of later NSAID use ( P trend = .02) ( Table 2 ). However, subjects ran-
domly assigned to either active aspirin arm who used NSAIDs only 
sporadically during observational follow-up were no longer at a 
reduced risk of adenomas compared with placebo subjects who also 
were sporadic NSAID users (adjusted RR = 1.00, 95% CI = 0.80 to 
1.24), nor were they at increased risk. There was no association 
between NSAID use during the posttreatment period and the risk 
of adenomas among subjects who had been randomly assigned to 
placebo ( Table 2 ). We obtained similar results when we evaluated 
the risk of small tubular adenomas (data not shown). 
 The protective effect of low-dose aspirin against colorectal 
adenomas during the treatment phase persisted only among sub-
jects who continued to take NSAIDs during the observational 
follow-up phase ( P trend with NSAID use = .03) ( Table 2 ). Subjects 
randomly assigned to 81 mg of aspirin who later used NSAIDs at 
least 4 days per week had a markedly reduced risk of all adenomas 
compared with placebo subjects who were at most sporadic 
NSAID users (39.9% vs 26.8%; adjusted RR = 0.62, 95% CI = 0.39 
to 0.98) ( Table 2 ). The reduction in unadjusted absolute risk was 
13.1 percentage points (95% CI = −0.3 to 26.5 percentage points ) 
( P = .07). We obtained similar results when we restricted the refer-
ence category to placebo subjects who took no NSAIDs after the 
end of randomized treatment (data not shown). 
 High-dose aspirin did not confer a statistically signifi cant 
reduction in adenoma risk during the randomized treatment 
period of the trial ( Table 2 ). In this analysis, subjects who were 
randomly assigned to high-dose aspirin and who later were fre-
quent users of NSAIDs had a nonstatistically signifi cantly lower 
risk for all adenomas than placebo subjects who were at most spo-
radic NSAID users (30.6% vs 39.9%; adjusted RR = 0.72, 95% 
CI = 0.46 to 1.12;  P trend with NSAID use = .08). The corresponding 
 Table 2 .  Risk of adenoma with randomized aspirin treatment and subsequent NSAID use * 
 Study phase
No. of subjects with adenoma/
Total no. of subjects (%)
Adjusted RR 
(95% CI)  P trend † 
 Randomized trial ‡  
  Placebo 143/285 (50.2) 1.00 (reference)  
  Aspirin 256/565 (45.3) 0.90 (0.77 to 1.05)  
  Low-dose aspirin 118/284 (41.6) 0.84 (0.70 to 1.00)  
  High-dose aspirin 138/281 (49.1) 0.96 (0.81 to 1.14) NA 
 Posttreatment observational follow-up §  
  Aspirin treatment group   Posttreatment NSAID use ||    
   Placebo    <2 days per week 81/203 (39.9) 1.00 (reference)  
   Placebo    2 – 4 days per week 12/32 (37.5) 1.02 (0.61 to 1.69)  
   Placebo    ≥ 4 days per week 18/43 (41.9) 0.91 (0.59 to 1.39) .46 
   Aspirin    <2 days per week 153/386 (39.6) 1.00 (0.80 to 1.24)  
   Aspirin    2 – 4 days per week 21/64 (32.8) 0.84 (0.57 to 1.25)  
   Aspirin    ≥ 4 days per week 30/105 (28.6) 0.67 (0.47 to 0.94) .02 
   Low-dose aspirin    <2 days per week 76/194 (39.2) 1.01 (0.78 to 1.30)  
   Low-dose aspirin    2 – 4 days per week 8/28 (28.6) 0.78 (0.43 to 1.41)  
   Low-dose aspirin    ≥ 4 days per week 15/56 (26.8) 0.62 (0.39 to 0.98) .03 
   High-dose aspirin    <2 days per week 77/192 (40.1) 0.98 (0.76 to 1.27)  
   High-dose aspirin    2 – 4 days per week 13/36 (36.1) 0.89 (0.55 to 1.43)  
   High-dose aspirin    ≥ 4 days per week 15/49 (30.6) 0.72 (0.46 to 1.12) .08 
 *  Included 833 participants who completed study questionnaires and had at least one colonoscopy during the posttreatment follow-up interval. “Aspirin” refers to 
both doses combined. RR = relative risk; CI = confidence interval; low-dose aspirin = 81 mg; high-dose aspirin = 325 mg; NA = not applicable; NSAIDs = non-
steroidal anti-inflammatory drug. 
 †  Relative risks adjusted for age, sex, clinical center, number of lifetime adenomas before randomization, and duration of follow-up until the end of randomized 
treatment. 
 ‡  P value for the response trend with NSAID frequency of use among each randomized treatment group from a two-sided Wald test. 
 §  Relative risks adjusted for aspirin dose, age, sex, center, body mass index, time to year 3 study colonoscopy (overall aspirin treatment effects) or time to first 
colonoscopy after the end of randomized treatment (posttreatment NSAID effects), number of lifetime adenomas before randomization, and presence of 
adenomas during the randomized period. 
 ||  NSAID use defined as the average number of days per week subjects took NSAIDs between the end of randomized aspirin treatment and the subsequent 
posttreatment colonoscopy. 
jnci.oxfordjournals.org   JNCI | Articles 273
reduction in unadjusted absolute risk was 9.3 percentage points 
(95% CI = −5.3 to 23.8 percentage points) ( P = .23). 
 The association between randomized aspirin treatment with 
later NSAID use and the risk of colorectal adenoma in the post-
treatment observational period was not statistically signifi cantly 
modifi ed by randomized folate treatment assignment ( P = .89). 
Stratifi cation by adenoma occurrence during the randomized 
aspirin treatment period of the trial did not modify the post-
treatment results statistically signifi cantly either. Among sub-
jects who were diagnosed with at least one adenoma during 
study aspirin treatment, randomization to low-dose aspirin with 
later frequent NSAID use was associated with a 50% reduction 
in the risk of adenomas (adjusted RR vs placebo subjects with 
sporadic NSAID use = 0.50, 95% CI = 0.25 to 0.99). Among 
those without adenomas during the randomized treatment 
period, the reduction in risk was 22% (adjusted RR vs placebo 
subjects with sporadic NSAID use = 0.78, 95% CI = 0.41 to 
1.47). The multiplicative interaction between the frequency of 
NSAID use during observational follow-up and the detection of 
adenomas during the treatment period in the low-dose aspirin 
group was not statistically signifi cant ( P = .60). The results for 
high-dose aspirin were similar to those for low-dose aspirin 
(data not shown). 
 Findings regarding the risk of advanced lesions during the ran-
domized treatment phase are summarized in  Table 3 . During the 
randomized treatment period, aspirin (81 or 325 mg) conferred a 
protective effect against advanced lesions compared with placebo 
(RR = 0.73, 95% CI = 0.50 to 1.09), and the effect was more pro-
nounced, although not statistically signifi cant, in the low-dose 
aspirin group (adjusted RR = 0.66, 95% CI = 0.41 to 1.07). A com-
parable analysis for the posttreatment follow-up period was ham-
pered by the small number of advanced lesions detected. 
Therefore, we conducted this analysis by combining the moder-
ate and frequent NSAID users into a single category of NSAID 
users ( Table 3 ). None of the relative risks was statistically signifi -
cant. However, the lower limit of the confi dence limits for each 
exposure group included reductions in risk as large as 50% in com-
parison with the reference category, and each point estimate sug-
gested reduced risks, except for subjects randomized to high-dose 
aspirin who subsequently were NSAID users. 
 All analyses were repeated with aspirin and nonaspirin NSAIDs 
considered separately. The fi ndings were similar to those shown 
above (data not shown). 
 Discussion 
 In this analysis of adenoma occurrence after the end of randomized 
aspirin treatment, we found that continued use of aspirin and/or 
other NSAIDs extended the chemopreventive effects of aspirin 
that were seen during the treatment period. There was an apparent 
strengthening of the chemopreventive effect associated with 
NSAID use of at least 4 days per week on average. There was no 
evidence of tachyphylaxis or tolerance, nor was there an indication 
of a rebound in the incidence of adenomas after the end of ran-
domized treatment. Although our numbers for advanced lesions 
were too small to draw confident conclusions, low-dose aspirin and 
subsequent NSAID use also seemed to yield a persistent reduction 
in risk. These findings imply that aspirin does not lose its antine-
oplastic properties over time and that these effects persist and may 
even be accentuated with prolonged NSAID use. 
 Table 3 .  Risk of advanced adenomas with randomized aspirin treatment and subsequent NSAID use * 
 Study phase
No. of subjects with adenoma/ 
Total no. of subjects (%)
Adjusted RR 
(95% CI) 
 Randomized trial † 
  Placebo 38/285 (13.3) 1.00 (reference) 
  Aspirin 56/565 (9.9) 0.73 (0.50 to 1.09) 
  Low-dose aspirin 26/284 (9.2) 0.66 (0.41 to 1.07) 
  High-dose aspirin 30/281 (10.7) 0.81 (0.51 to 1.29) 
 Posttreatment observational follow-up ‡ 
  Aspirin treatment group   Posttreatment NSAID Use §   
   Placebo    <2 days per week 25/203 (12.3) 1.00 (reference) 
   Placebo    ≥ 2 days per week 4/75 (5.3) 0.44 (0.15 to 1.27) 
   Aspirin    <2 days per week 28/386 (7.3) 0.61 (0.35 to 1.04) 
   Aspirin    ≥ 2 days per week 14/169 (8.3) 0.68 (0.35 to 1.32) 
   Low-dose aspirin    <2 days per week 12/194 (6.2) 0.54 (0.27 to 1.08) 
   Low-dose aspirin    ≥ 2 days per week 3/84 (3.6) 0.31 (0.09 to 1.04) 
   High-dose aspirin    <2 days per week 16/192 (8.3) 0.67 (0.36 to 1.25) 
   High-dose aspirin    ≥ 2 days per week 11/85 (12.9) 0.99 (0.48 to 2.05) 
 *  Included 833 participants who completed study questionnaires and had at least one colonoscopy during the posttreatment follow-up period. “Aspirin” refers 
to both doses combined. RR = relative risk; CI = confidence interval; low-dose aspirin = 81 mg; high-dose aspirin = 325 mg; NSAIDs = nonsteroidal 
anti-inflammatory drug. 
 †  Relative risks adjusted for age, sex, clinical center, number of lifetime adenomas before randomization, and duration of follow-up until the end of randomized 
treatment. 
 ‡  Relative risks adjusted for aspirin dose, age, sex, center, body mass index, time to year 3 study colonoscopy (overall aspirin treatment effects) or time to first 
colonoscopy after the end of randomized treatment (posttreatment NSAID effects), number of lifetime adenomas before randomization, and presence of 
adenomas during the randomized period. 
 §  NSAID use defined as the average number of days per week subjects took NSAIDs between the end of randomized aspirin treatment and the subsequent 
posttreatment colonoscopy. 
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 During the randomized treatment phase of the study, low-
dose aspirin had a chemoprotective effect against adenomas, 
whereas high-dose aspirin did not ( 1 ). This fi nding was unex-
pected. In this secondary analysis, both doses of aspirin were 
associated with a decreased risk for all adenomas among sub-
jects who frequently used NSAIDs after the end of randomized 
aspirin treatment, although the risk reduction was not statisti-
cally signifi cant among subjects who had been randomly 
assigned to high-dose aspirin. These results seem to support the 
hypothesis that chance was responsible for the dose – response 
pattern observed in the analysis of adenoma occurrence during 
randomized aspirin treatment ( 1 ). For advanced lesions, small 
numbers of endpoints hampered the analysis, and no fi rm con-
clusions can be drawn regarding the delayed effects of aspirin 
treatment. 
 A recent observational study reported that the use of two stan-
dard tablets of aspirin per week (equivalent to a dose of 650 mg 
of aspirin) was associated with a statistically signifi cant reduction 
in the risk of colorectal cancer, with a trend of decreasing risk 
with increasing number of tablets taken per week ( 9 ). A more 
recent analysis of data from two large randomized trials with 
aspirin concluded that a daily dose of 300 mg or more of aspirin 
taken for 1 – 7 years could prevent colorectal cancer after a latency 
period of about 10 years ( 10 ). Our observational follow-up data 
suggest a trend of reduced risk of colorectal adenomas with 
increased frequency of NSAID use after 3 years of daily aspirin 
use. The implications of this secondary prevention of adenomas 
on the incidence of colorectal cancer are not clear, but our fi nd-
ings are consistent with the two studies mentioned above, given 
that most cancers in the colon and rectum evolve from the same 
types of precancerous neoplastic lesions that we studied ( 11 ). It is 
reasonable to argue that by reducing the incidence of colorectal 
adenomas, long-term use of NSAIDs could reduce the future risk 
of colorectal cancer. 
 In this analysis, we did not fi nd an increased risk of adenomas 
after the end of randomized treatment. Indeed, for advanced 
adenomas, the chemopreventive potency of aspirin seemed to 
persist even in the absence of later NSAID use, suggesting a car-
ryover effect of the aspirin treatment, at least for a few years. 
Such an effect might occur if, for example, aspirin has a longer 
latent period of effect for advanced adenomas than for small 
tubular adenomas. However, as mentioned above, the numbers of 
advanced adenomas are too small and our statistical power is too 
limited to rule out chance as a possible explanation for this 
result. 
 It is unclear why we found no reduction of adenoma risk associ-
ated with later NSAID use among subjects who had been ran-
domly assigned to placebo. Previous studies have described inverse 
associations after relatively short exposures of 1 – 3 years ( 3 , 12 ). In 
this analysis, it is possible that longer and/or more intense use of 
these drugs would be required to see such an effect in placebo 
subjects because of the 3 years of NSAID abstinence during the 
randomized treatment period of our study. 
 There is extensive evidence supporting the antineoplastic 
properties of aspirin and other NSAIDs ( 2 – 4 , 13 – 15 ). Regarding 
colorectal adenomas and colorectal cancer, experimental studies 
( 16 – 21 ) have reported a protective effect of aspirin. More 
importantly, results of observational studies ( 5 , 22 – 27 ) and ran-
domized clinical trials ( 1 , 10 , 12 , 28 , 29 ) have consistently supported 
the inverse association of aspirin with adenoma risk. The proposed 
mechanisms underlying the anticarcinogenic activity of aspirin and 
other NSAIDs may be related to their ability to inhibit the activity 
of COX enzymes. These enzymes are responsible for the synthesis 
of prostaglandins and other metabolites that are associated with 
infl ammatory processes and carcinogenesis ( 19 , 30 – 35 ). Some 
experimental studies ( 32 , 36 – 42 ) have described anticarcinogenic 
mechanisms independent of COX enzymes. Indeed, aspirin in the 
doses we used has relatively little effect on the activity of COX-2 
( 43 ), the enzyme isoform that has been most frequently associated 
with neoplastic processes, a fi nding that supports the idea that 
COX-2 inhibition may not be necessary for the chemopreventive 
effects of NSAIDs. 
 Our study has several strengths. Compliance with the study 
regimen was excellent: More than 85% of subjects reported taking 
study pills at least 90% of the time, even during the year before the 
year 3 colonoscopy that marked the end of the randomized aspirin 
treatment period ( 1 ). We had a large sample size: Of the 1121 
subjects originally randomly assigned to placebo or aspirin, 1007 
agreed to continue in the follow-up phase and 850 had at least one 
colonoscopy. Furthermore, all biopsy specimens were examined in 
a blinded fashion by a single study pathologist in a uniform end-
point review ( 1 , 8 ). 
 This study also has a number of limitations. Most importantly, 
because in this analysis, the posttreatment follow-up period was 
observational, our fi ndings are susceptible to bias and confounding. 
For example, posttreatment NSAID use was based on self-report 
and thus, our categorization of subjects according to reported use 
may not have been entirely accurate. In addition, frequent NSAID 
users were older than the other subjects and tended to have a 
higher body mass index. Although our estimates were adjusted for 
these factors, we could not deal similarly with other potentially 
confounding factors that we did not identify. Subjects in this analy-
sis were a higher risk subset of an already selected population that 
met the eligibility requirements for the randomized trial because 
the participants with neoplastic lesions detected during the treat-
ment period were more likely to have a colonoscopy during the 
posttreatment phase than those who were free of adenomas. Thus, 
our study subjects are not representative of the general population. 
Furthermore, small numbers of advanced lesions limited our statis-
tical power and prevented us from drawing fi rm conclusions 
regarding the association of NSAIDs with this endpoint. 
 To evaluate response trends, we relied on the reported fre-
quency of use because our questionnaires did not capture dose 
information, and this is another important weakness of our analy-
sis. Furthermore, there was no uniform interval between the end 
of the randomized study and the fi rst posttreatment colonoscopy. 
However, our statistical models were adjusted for this varying time 
at risk, and it is unlikely that it affected our results. It is possible 
that the particular characteristics of the NSAIDs taken after the 
end of randomized treatment could have played a role in our fi nd-
ings. For example, specifi c types of NSAIDs and/or higher doses 
could have been responsible for the apparent strengthening of the 
chemopreventive effect of aspirin during the subsequent follow-up 
interval. 
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 In summary, our study provides further evidence of the poten-
tial chemopreventive effect of NSAIDs against colorectal ade-
nomas in patients with a history of these polyps. Our fi ndings 
suggest that prolonged and frequent use of these agents can have 
strong benefi cial effects. We did not fi nd either loss of effective-
ness with continued use or increased risk following discontinuation 
of use. This study raises the possibility that NSAIDs taken 4 – 7 
days per week might be suffi cient to prevent adenomas and, by 
implication, colorectal cancer. Because our results imply that the 
strength of the inverse association between NSAID use and ade-
noma risk may increase with frequency of use and because more 
frequent use is also likely to cause more adverse events, further 
investigation is important to understand ways to maximize the pos-
sible benefi ts of these drugs while minimizing their potential 
harms. 
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